Clinical trial
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory…
NCT00384553 · University of Magdeburg, Other · Unknown status
Key facts
| NCT number | NCT00384553 |
|---|---|
| Title | Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma |
| Official title | Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma |
| Lead sponsor | University of Magdeburg, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, DHAP, TEC, autologous stem cell transplantation |
| Enrollment | 30 |
| Start date | Jun 1, 2004 |
| Completion | Jun 1, 2010 |
| First posted | Oct 6, 2006 |
| Last update posted | Oct 6, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: